Josefin-Beate Holz, an experienced drug developer, has joined Storm Therapeutics Ltd as chief medical officer to help advance the company’s small molecule therapies modulating RNA epigenetics. Storm’ lead product, a METTL3 inhibitor, is moving into enabling studies for a first clinical trial. Dr Holz has held executive positions at Ablynx (now part of Sanofi SA), Gilead Sciences Inc and Bristol-Myers Squibb Co. She has worked on more than 50 disease targets at various stages of clinical validation in oncology, immunology and other indications. Dr Holz received a PhD in haematology oncology from the University of Marburg, Germany.
Storm Therapeutics announced the appointment on 23 June 2020.
Copyright 2020 Evernow Publishing Ltd